| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-142 |
Sentence |
denotes |
Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. |
| T1 |
0-142 |
Sentence |
denotes |
Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. |
| TextSentencer_T2 |
143-233 |
Sentence |
denotes |
beta-Oxidation of long-chain fatty acids provides the major source of energy in the heart. |
| T2 |
143-233 |
Sentence |
denotes |
beta-Oxidation of long-chain fatty acids provides the major source of energy in the heart. |
| TextSentencer_T3 |
234-414 |
Sentence |
denotes |
Defects in enzymes of the beta-oxidation pathway cause sudden, unexplained death in childhood, acute hepatic encephalopathy or liver failure, skeletal myopathy, and cardiomyopathy. |
| T3 |
234-414 |
Sentence |
denotes |
Defects in enzymes of the beta-oxidation pathway cause sudden, unexplained death in childhood, acute hepatic encephalopathy or liver failure, skeletal myopathy, and cardiomyopathy. |
| TextSentencer_T4 |
415-575 |
Sentence |
denotes |
Very-long-chain acyl-CoA dehydrogenase [VLCAD; very-long-chain-acyl-CoA:(acceptor) 2,3-oxidoreductase, EC 1.3.99.13] catalyzes the first step in beta-oxidation. |
| T4 |
415-575 |
Sentence |
denotes |
Very-long-chain acyl-CoA dehydrogenase [VLCAD; very-long-chain-acyl-CoA:(acceptor) 2,3-oxidoreductase, EC 1.3.99.13] catalyzes the first step in beta-oxidation. |
| TextSentencer_T5 |
576-672 |
Sentence |
denotes |
We have isolated the human VLCAD cDNA and gene and determined the complete nucleotide sequences. |
| T5 |
576-672 |
Sentence |
denotes |
We have isolated the human VLCAD cDNA and gene and determined the complete nucleotide sequences. |
| TextSentencer_T6 |
673-878 |
Sentence |
denotes |
Polymerase chain reaction amplification of VLCAD mRNA and genomic exons defined the molecular defects in two patients with VLCAD deficiency who presented with unexplained cardiac arrest and cardiomyopathy. |
| T6 |
673-878 |
Sentence |
denotes |
Polymerase chain reaction amplification of VLCAD mRNA and genomic exons defined the molecular defects in two patients with VLCAD deficiency who presented with unexplained cardiac arrest and cardiomyopathy. |
| TextSentencer_T7 |
879-1041 |
Sentence |
denotes |
In one, a homozygous mutation in the consensus dinucleotide of the donor splice site (g+1-->a) was associated with universal skipping of the prior exon (exon 11). |
| T7 |
879-1041 |
Sentence |
denotes |
In one, a homozygous mutation in the consensus dinucleotide of the donor splice site (g+1-->a) was associated with universal skipping of the prior exon (exon 11). |
| TextSentencer_T8 |
1042-1272 |
Sentence |
denotes |
The second patient was a compound heterozygote, with a missense mutation, C1837-->T, changing the arginine at residue 613 to tryptophan on one allele and a single base deletion at the intron-exon 6 boundary as the second mutation. |
| T8 |
1042-1272 |
Sentence |
denotes |
The second patient was a compound heterozygote, with a missense mutation, C1837-->T, changing the arginine at residue 613 to tryptophan on one allele and a single base deletion at the intron-exon 6 boundary as the second mutation. |
| TextSentencer_T9 |
1273-1492 |
Sentence |
denotes |
This initial delineation of human mutations in VLCAD suggests that VLCAD deficiency reduces myocardial fatty acid beta-oxidation and energy production and is associated with cardiomyopathy and sudden death in childhood. |
| T9 |
1273-1492 |
Sentence |
denotes |
This initial delineation of human mutations in VLCAD suggests that VLCAD deficiency reduces myocardial fatty acid beta-oxidation and energy production and is associated with cardiomyopathy and sudden death in childhood. |